FDA Issues CRL to Salix/ Progenics Constipation Drug
By Catherine Shaffer
Tuesday, July 31, 2012
A day of anticipation ended in disappointment as Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals Inc. received a complete response letter late Friday from the FDA for injectable Relistor (methylnaltrexone bromide) for opioid-induced constipation in adult patients with chronic, noncancer pain, which has not responded to treatment with laxatives.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.